

## MASTERMIND®

## Use Case Scenario: Searching Mastermind by Variant

© 2017 GENOMENON® info@genomenon.com https://www.genomenon.com

## Searching Mastermind by Variant

Mastermind can be used to search for all publications associated with a known, previously reported genetic variant. As new articles describing a specific disease-causing variant are being published daily, using Mastermind to keep up-to-date with the latest information and clinical findings can help guide and accelerate precision medicine initiatives in the clinic.

In the following example, we will use Mastermind to search for the p.G551D variation in the *CFTR* gene. The p.G551D variant, in which the amino acid glycine is replaced with aspartic acid at position 551 in the protein, results in a dysfunctional cell surface protein that is unable to transport chloride through a channel.

From the Mastermind home page, enter "CFTR" in the Gene field to automatically enable the Variant query box.



The results page will show you a list of MeSH disease terms where this gene-variant pair has been described in the full text, title, and abstract of any corresponding publications. The results are also sorted with the highest number of publications appearing at the top. Next, click on the disease term "CYSTIC FIBROSIS" to go to an overview page with information about this specific disease-gene-mutationassociation.

🛞 MASTERMIND* Disease 🛛 🗙 CFTR	× G551D × Q Show Advanced Search	Home Contact Us Mastermind Suite My Account A
Disease	Articles	Gene
ALL	2.0k	CFTR
FIBROSIS	1.8k	CFTR
CYSTIC FIBROSIS	1.8k	CFTR
HUMANISM	326	CFTR
LUNG DISEASES	258	CFTR
INDIVIDUALITY	240	CFTR
INDIVIDUATION	240	CFTR
PANCREATITIS	220	CFTR
GENERALIZATION (PSYCHOLOGY)	217	CFTR
SWEATING	217	CFTR
INHIBITION (PSYCHOLOGY)	197	CFTR

In the bottom left panel, labeled "Variants", you will see the p.G551D variant, along with p.G551del, since our search term did not exclude this variant.

At the top of this detail page you will see a toolbar with abbreviated terms that further qualify the publications by various subcategories. This will be handy since even when searching by a Disease-Gene-Variant trio, there are still 1.7k articles to sort through. Mousing over each term will reveal the full names of each subcategory. The treatment category (Rx) itemizes those publications where a therapeutic treatment is likely to have been described. To view these publications, click on the "Rx" ico. This will open a menu with additional search terms that can be used to further filter your results.

The "drug" field will generate a list of publications (counted in parenthesis) that describe a specific drug therapy administered in CF patients harboring the CFTR-p.G551D variant. To generate this list, you will first need to click on the "Disable All" option to deselect all search terms, then click on "drug".

())) MAS	TERMIND <sup>®</sup> Cystic Fibrosis	× CFTR × G551D × Q Show A	dvanced Search		Home Contact Us Mastermind Suite	e▶ My A	ccount	•			
CYSTIC FIE	BROSIS	208 Dx Px Rx Fx	Ix Mx SN	р нү	CR RT		CI	TR			
Treatment - Articles that include information related to treatments and therapies.											
	Enable A	All			Disable All						
treatment (	413)	drug (208)		com	pound (176)						
pharmaceu	itical (30)	therapy (320)		dos	e (72)						
dosage (3)		[a-z]*ib (194)		[a-z]	]*ab (32)						
drug resista	ance	resistance mechanism									
VARIANIS	Filter by variant: (	3551D Sort by: Full-Text Hits • •	ARTICLES EXPOR		Son by:	ssociation	strengtn	• •			
NAME	CDNA POSITIONS	FULL-TEXT PUBMED DATA	JOURNAL	DATE	TITLE	MATCHES					
p.G551D	c.1651, c.1652, c.1653	1.7k 266	J. Biol. Chem.	2005 Nov 25	Differential sensitivity of the cystic fibrosis (CF)-associa.	. 1 127	1	89			
			🖹 🍳 Sheng Li Xue Bao	2015 Apr 25	[Polymethoxylated flavonoids activate cystic fibrosis tr	1 184	1	1			
p.G551del	c.1651, c.1652, c.1653	33 0 -	Assay Drug Dev Technol	2010 Nov 4	Identification of synergistic combinations of F508del cy.	. 1 122	1	1			
			Ann Pharmacother	2012 Jun 26	Cystic fibrosis transmembrane conductance regulator	1 99	1	21			
			J. Biol. Chem.	2007 Dec 30	Mechanism of Q551D-CFTR (cystic fibrosis transmemb.	1 31	1	98 🗸			
PUBMED DATA	PMID: 16311240	•	FULL-TEXT MATCHES	Show PDF	F PMID: 16311240 Show	r: Gene r	matches	• •			
Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to CFTR Fibrosis Transmembrane Conductance Regulator (GFTR) of the cystic fibrosis transmembrane conductance regulator (CFTR) CI-channel.			Regulator (CFTR)			<b>^</b>					
J. Biol. Chem.	2005 Nov 24	Cai Z	regulator	ic librosis (CP) I	is caused by loss of func-tion of the cystic librosis trainsm	embrane con	ductance	e - 1			
The genetic disease cystic fibrosis CF) is caused by loss of function of the cystic fibrosis transmembrane conductance		CFTR (GFTR) CI									
motifs that are essential components of the ATP-binding sites of CFIR. Both mutants severely disrupt CFIR channel gating by		CFTR essential components of the ALP-binding sites of CFTR CFTR mutants severely disrupt CFTR channel gating by decreasing mean									
the gating defects of G551D- and G1349D-CFTR and understand better how these agents work, we used the patch clamp			CFTR CFTR channel gating								
technique to study	the effects on G551D- and G1349D-CFIR of phloxine	B, pyrophosphate (PP(i)), and 2'-deoxy ATP (2'-dATP),	CFTR Using the ATP-driven nue	cleotide-binding	domain dimerization model of CFTR			*			

Publications can then be browsed in the "Articles" panel in the center right. The default view rank orders the publications by the strength of the term associations in the full text, title, and abstract, but they can also be sorted by Publication Date, Journal Name, and Impact Factor. Clicking on the "Export" icon will then export the list of filtered publications (PubMed ID, Title, and Journal in .csv format) which can be saved locally.

In summary, searching Mastermind with a gene name and known variant will enable you to 1) see all publications associated with a gene-variant-disease association and 2) filter the search results by subcategory to identify subsets of publications describing a particular treatment, therapy or biological outcome (among others).



## We are pleased that you are interested in our software and we look forward to learning from your experience.

If any questions arise, please do not hesitate to contact us.

info@genomenon.com